InMed Pharmaceuticals (INM) Change in Receivables (2019 - 2025)
InMed Pharmaceuticals (INM) posted quarterly Change in Receivables of -$159977.0 for Q4 2025, down 606.46% year-over-year from $31587.5 in Q4 2024, and down 30.96% quarter-over-quarter from -$122160.0 in Q3 2025.
InMed Pharmaceuticals (INM) Change in Receivables (2019 - 2025) Analysis & Trends
InMed Pharmaceuticals' Change in Receivables history runs 7 years deep, the most recent figure standing at -$159977.0 for Q4 2025.
- In Q4 2025, Change in Receivables fell 606.46% year-over-year to -$159977.0; the TTM figure through Dec 2025 stood at -$77178.0 (up 30.03% YoY), while the FY2025 annual figure was $114690.0, up 24.07% from the prior year.
- Change in Receivables for Q4 2025 stood at -$159977.0, down from -$122160.0 in the prior quarter.
- The five-year high for Change in Receivables was $207019.0 in Q4 2023, with the low at -$165188.0 in Q1 2024.
- The 5-year median for Change in Receivables is $1142.5 (2021), against an average of $2061.0.
- Peak annual rise in Change in Receivables reached 14451.57% in 2022, while the deepest fall reached 2592.58% in 2022.
- InMed Pharmaceuticals' Change in Receivables stood at -$638.0 in 2021, then soared by 14451.57% to $91563.0 in 2022, then jumped by 126.09% to $207019.0 in 2023, then slumped by 110.94% to -$22645.0 in 2024, then tumbled by 606.46% to -$159977.0 in 2025.
- Business Quant data shows INM's Change in Receivables at -$159977.0 in Q4 2025, -$122160.0 in Q3 2025, and $99715.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.42 Mn | 1.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -159,977.00 |
| Dec 31, 2025 | -159,977.00 |
| Sep 30, 2025 | -122,160.00 |
| Sep 30, 2025 | -122,160.00 |
| Jun 30, 2025 | 99,715.00 |
| Jun 30, 2025 | 99,715.00 |
| Mar 31, 2025 | 105,244.00 |
| Mar 31, 2025 | 105,244.00 |
| Dec 31, 2024 | -22,645.00 |
| Dec 31, 2024 | -22,645.00 |
| Sep 30, 2024 | -67,624.00 |
| Sep 30, 2024 | -67,624.00 |
| Jun 30, 2024 | 145,157.00 |
| Jun 30, 2024 | 145,157.00 |
| Mar 31, 2024 | -165,188.00 |
| Mar 31, 2024 | -165,188.00 |
| Dec 31, 2023 | 207,019.00 |
| Dec 31, 2023 | 207,019.00 |
| Sep 30, 2023 | -94,549.00 |
| Sep 30, 2023 | -94,549.00 |